Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS
Nonetheless, the net effect from the meta-analysis supports the combined therapy, although it exhibits considerable heterogeneity and includes very few studies
However, it is also one of the 10 drugs that are subject to Medicare price negotiations
(Michael Siluk/UCG/Universal Images Group via Getty Images / Getty Images) NOVO NORDISK TO SELL WEIGHT-LOSS DRUG FOR $499 TO ELIGIBLE CUSTOMERS Novo Nordisk is a Danish healthcare company which develops treatments for an array of illnesses, including diabetes and obesity drugs
To view a copy of this license, visit About this article Cite this article Miranda, P.H.d.A., Lacerda, K.C.D., Arajo, C.M